Martin David Harp

The collaboration, fueled by a $5 million donation from Knights Templar Eye Foundation (KTEF), will introduce a free and open VR simulation program for ophthalmologists and trainees worldwide.

Eight patients were able to receive a second implant at 21 weeks, with no product related adverse effects.

EVO ICLs, which evolved from early generation ICLs, offer a lens-based alternative for the correction/reduction of refractive error in people who currently use glasses and/or contact lenses for vision correction.

Aldeyra Therapeutics encounters a significant setback, with its stock value plummeting nearly 70%. The FDA indicates a potential Complete Response Letter (CRL) for reproxalap, a dry eye treatment, despite a scheduled Prescription Drug User Fee Act (PDUFA) date of November 23, 2023.

AffaMed Technologies is the joint venture between AffaMed Therapeutics and SIFI.

The Phase 3 DIAMOND trial of OCS-01 in Diabetic Macular Edema (DME) presents encouraging results, meeting primary and secondary endpoints.

Prevent Blindness emphasizes the importance of proper eye protection, as exposure to the sun during an eclipse can cause "eclipse blindness" or retinal burns, which can be temporary or permanent.

A groundbreaking study conducted by the International Agency for the Prevention of Blindness (IAPB) and Kevin Frick, PhD, from Johns Hopkins University reveals that prioritizing better eye health could inject a staggering $50.4 billion annually into the US economy.

Held the second Thursday each October, World Sight Day is an annual day of awareness to focus global attention on blindness and vision impairment.

Academy’s 2023 program taking place in San Francisco.

According to the company, study enrollment is planned to commence during Q1 2024 following IND allowance by the FDA.

The Person of Vision Award gala will be held on March 14, 2024.

This milestone was announced by Clearside Biomedical, Inc., Arctic Vision's partner. ARCATUS, also known as XIPERE®, utilizes a revolutionary suprachoroidal delivery platform, offering new hope to patients in China suffering from this vision-threatening condition.

The data was presented in a poster titled at the American Thyroid Association (ATA).

The collaboration will drive an effort to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with serious eye diseases.

An increase in sexually transmitted infections may be causing an increase in number of eye infections.

The MyopiaX-1 trial studies MyopiaX, a smartphone application that aims to slow the progression of myopia, or nearsightedness, in children and adolescents.

The effort will capture the real-life stories of patients and eye care professionals around the world.

Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.

As a gold medalist with profound vision loss, she will lead advocacy efforts for people with glaucoma that are designed to empower patients to participate actively in their glaucoma treatment journey

The theme calls on employers, insurers, and policy makers to consider how they can contribute to improved access to vision and eye health care.

The week of September 18-24 will be dedicated to educating the public on IEDs such as uveitis, keratitis, conjunctivitis and more.

The study monitored real-world patient experiences for up to 12 months post cataract surgery with implantation of either AcrySof IQ Vivity or AcrySof IQ Vivity Toric presbyopia-correcting intraocular lens (PCIOL).

Walgreens Boots Allianc Inc. and CVS Health are among the companies the FDA sent letters to for violating federal law.

Targeting the interleukin-11 receptor, LASN01 is a potential treatment for fibro-inflammatory diseases including thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF).

Debbie Allen, an award-winning actress, dancer, choreographer, singer-songwriter, director and producer is teaming up with Prevent Blindness and Regeneron for the Gr8 Eye Movement, an awareness campaign that aims to educate and encourage those who are at risk of certain retinal diseases to prioritize their eye health.

In this key role, Weil will lead the organization to commercial readiness from designing launch strategies for the US and globally.

The study examines the effectiveness of PL9643 for the treatment of patients with dry eye disease.

The trial is for the MINIject MIGS device for patients with primary open-angle glaucoma.

Jeff Todd talks about the campaign and partnering with actress Debbie Allen to help gain awareness on eye health.